URAC vs ACHC Pharmacy Accreditation — Side-by-Side Comparison
Last updated: April 2026
URAC and ACHC are the two dominant pharmacy accreditation bodies in the United States. Understanding which program your organization needs — or whether you need both — requires comparing payer preference, standards focus, deeming authority, specialty designations, survey process, and renewal requirements. This comparison is prepared by IHS, led by Thomas G. Goddard, JD, PhD, former Chief Operating Officer and General Counsel of URAC.
At a Glance: URAC vs ACHC Pharmacy Accreditation
URAC — Utilization Review Accreditation Commission
URAC is the dominant pharmacy accreditation credential for commercial payer network access, preferred by approximately 66% of commercial payers when evaluating pharmacy network partners (Pharmacy Times). URAC's pharmacy programs emphasize clinical patient management, operational quality metrics, and the five core performance measures that commercial payers use to tier pharmacy networks. URAC accreditation does not carry Medicare/Medicaid deeming authority for pharmacy.
ACHC — Accreditation Commission for Health Care
ACHC is the second most prevalent pharmacy accreditation credential. ACHC is a CMS-approved deeming authority for certain pharmacy programs, meaning ACHC accreditation can satisfy Medicare/Medicaid certification requirements for applicable services. ACHC also offers specialty disease state designations — oncology, HIV, and rare and orphan diseases — that URAC does not. ACHC's focus is on pharmacy operations, patient care outcomes, and organizational management including fiscal and human resources.
The Third Option: CPPA
The Center for Pharmacy Practice Accreditation (CPPA) offers a third accreditation option. Both URAC and ACHC are generally considered to offer more rigorous accreditation processes than CPPA for specialty pharmacy, and CPPA has substantially lower market penetration in payer network access requirements. For most PBMs and pharmacy networks seeking commercial payer credentials, URAC and ACHC are the relevant programs.
Payer Preference and Market Access
Commercial Payer Network Access
URAC holds a significant advantage for commercial payer network access. Approximately 66% of commercial payers prefer URAC accreditation when evaluating pharmacy network partners (Pharmacy Times). For PBMs and pharmacy networks whose primary market is commercial managed care, URAC is the stronger first credential to pursue.
ACHC has growing commercial payer recognition but starts from a smaller base. If your primary payer contracts are with employers and commercial health plans, URAC is the higher-priority accreditation.
Limited Distribution Network (LDN) Access
For specialty pharmacies seeking access to pharmaceutical manufacturer limited distribution networks, both URAC and ACHC are recognized credentials. Manufacturers that grant exclusive dispensing contracts for high-cost specialty and orphan drugs use URAC and ACHC accreditation as gatekeeping requirements. Some manufacturers require URAC specifically; others accept either program. Review the specific LDN requirements of the manufacturers whose products are most strategically important to your organization.
Government Program Access
ACHC holds a clear advantage for government program access. ACHC is a CMS-approved deeming authority, meaning ACHC accreditation can satisfy Medicare/Medicaid certification requirements for applicable pharmacy services — creating direct regulatory value that URAC does not provide for pharmacy. Organizations whose primary market includes Medicare Part D or Medicaid pharmacy services should evaluate ACHC as the primary or co-primary credential.
Employer Group and TPA Requirements
Employer groups and third-party administrators contracting with PBMs increasingly specify URAC accreditation in their procurement requirements. URAC's commercial payer market preference extends into employer group procurement in many markets. Organizations serving employer group clients should verify whether their contract requirements specify URAC, ACHC, or either program.
Standards Focus and Accreditation Philosophy
URAC's Approach: Clinical Performance and Operational Metrics
URAC's pharmacy standards emphasize clinical patient management quality and measurable operational performance. URAC requires organizations to collect and report data on five core performance measures — drug-drug interaction management, call center performance, dispensing accuracy, distribution accuracy, and prescription turnaround time — and to demonstrate ongoing performance monitoring rather than just documenting intent.
URAC's standards modules include Customer Service, Communications and Disclosure (CSCD); Drug Management; Pharmacy Operations (Pharm-Op); Performance Monitoring and Improvement; Consumer Protection and Empowerment; and Risk Management. The CSCD module alone contains 13 standards focused on call center and patient assistance operations.
URAC accreditation requires ongoing performance reporting. Organizations must have functioning data collection infrastructure before the survey — not just policies describing what data will be collected.
ACHC's Approach: Organizational Operations and Outcomes
ACHC's pharmacy standards evaluate organizational structure, patient care outcomes, fiscal management, and human resources management alongside clinical operations. ACHC's approach is more organizational in scope — looking at how the pharmacy functions as an organization, not just how it processes prescriptions. This makes ACHC standards feel more familiar to organizations accustomed to organizational quality management frameworks.
ACHC also evaluates patient care outcome data, but the specific performance measure requirements differ from URAC's five-measure framework. ACHC's standards are updated periodically — organizations should review current ACHC standards documentation for the specific requirements applicable to their program version.
Specialty Pharmacy Standards: URAC v6.0 vs ACHC
For organizations operating specialty pharmacies (dispensing specialty medications with patient management services), URAC Specialty Pharmacy v6.0 (announced October 2025) and ACHC's specialty pharmacy program are the relevant credentials. URAC Specialty Pharmacy v6.0 covers nine operational modules across 40+ standards. ACHC offers specialty pharmacy accreditation with additional disease-state designations in oncology, HIV, and rare and orphan diseases — designations that URAC does not offer.
URAC Specialty Pharmacy Accreditation is preferred by approximately 66% of commercial payers for specialty pharmacy network access. ACHC's oncology and HIV designations provide differentiation for disease-state-focused specialty pharmacies that URAC's program does not.
Deeming Authority and Regulatory Status
ACHC: CMS-Approved Deeming Authority
ACHC is a CMS-approved deeming authority for certain healthcare programs. This means ACHC can conduct surveys to determine whether facilities meet Medicare and Medicaid certification requirements, and can conduct unannounced inspections. For pharmacy services that fall under CMS certification requirements, ACHC accreditation can satisfy those requirements directly — providing regulatory compliance value that URAC cannot.
The practical implication: pharmacies and pharmacy networks with significant Medicare or Medicaid business should evaluate ACHC as part of their accreditation strategy for the regulatory compliance benefit, not just the market access signal.
URAC: No Deeming Authority for Pharmacy
URAC accreditation does not carry Medicare/Medicaid deeming authority for pharmacy programs. URAC's value for pharmacy organizations is commercial payer network access and market differentiation — not regulatory compliance with CMS certification requirements. Organizations seeking both commercial payer credentials and CMS deeming will need dual URAC and ACHC accreditation.
Specialty Designations and Disease State Recognition
ACHC Specialty Designations
ACHC offers disease-state specialty designations alongside its core pharmacy accreditation that URAC does not provide:
- Oncology designation — recognition for pharmacies specializing in oncology drug management and patient support
- HIV designation — recognition for pharmacies specializing in HIV/AIDS medication management
- Rare and orphan disease designation — recognition for pharmacies serving rare disease patient populations
- Ambulatory infusion designation — recognition for ambulatory infusion pharmacy services
- Compounding pharmacy designation — recognition for compounding pharmacy operations
These designations are additive to core ACHC accreditation and allow specialty pharmacies to signal disease-state expertise to referring clinicians, pharmaceutical manufacturers, and payers who manage specific patient populations.
URAC Pharmacy Programs
URAC does not offer disease-state specialty designations for pharmacy. URAC's pharmacy programs — Pharmacy Services and Specialty Pharmacy — recognize operational quality and clinical management across the pharmacy's full patient population rather than distinguishing disease-state expertise. For specialty pharmacies whose competitive positioning is disease-state expertise (oncology, HIV, rare disease), ACHC designation provides differentiation that URAC cannot.
Survey Process Comparison
URAC Survey Process
The URAC pharmacy accreditation survey has three phases: desktop review (30-45 days), validation review, and committee decision. The desktop review evaluates submitted documentation — policies, procedures, and performance data — against applicable standards. URAC issues Requests for Information (RFIs) when documentation gaps are identified; organizations must respond within defined windows. The URAC accreditation committee makes the final accreditation decision.
URAC has streamlined its pharmacy accreditation process in recent years, reducing the overall accreditation timeline. For well-prepared organizations, URAC publishes a six-month completion timeline.
ACHC Survey Process
ACHC conducts an on-site survey — a direct inspection of your pharmacy operations — as part of its accreditation process. ACHC's status as a CMS deeming authority means it can conduct unannounced inspections. The on-site survey component is a substantive difference from URAC's primarily document-based review. Organizations preparing for ACHC accreditation must ensure that their operations match their submitted documentation in real time — not just for the scheduled survey, but for any unannounced ACHC visit.
The ACHC survey timeline is comparable to URAC's for overall accreditation, though the on-site preparation requirements are different in character.
Key Process Difference: Document Review vs On-Site Survey
The most significant process difference between URAC and ACHC pharmacy accreditation is the survey method. URAC's pharmacy accreditation is primarily a documentary review — surveyors evaluate what you submit. ACHC's on-site survey evaluates how your pharmacy actually operates on the day of inspection. Organizations with strong documentation practices but inconsistent operations face greater risk with ACHC. Organizations with strong operational practices but weak documentation face greater risk with URAC.
Dual Accreditation Strategy
When to Pursue Both URAC and ACHC
Dual URAC and ACHC accreditation is the appropriate strategy when:
- Your organization serves both commercial payer markets (where URAC is the preferred credential) and government programs (where ACHC provides deeming authority)
- You are seeking access to limited distribution networks where individual manufacturers require specific accreditation bodies
- Your specialty pharmacy focuses on oncology, HIV, or rare disease populations where ACHC designation provides disease-state differentiation
- Your largest employer group or health plan contracts specify both URAC and ACHC as preferred credentials
- You operate in a competitive specialty pharmacy market where dual accreditation signals the highest level of quality commitment
Sequencing Dual Accreditation
Organizations pursuing dual accreditation should not run both survey processes simultaneously unless they have dedicated compliance resources for each. The more common approach is to pursue URAC first (given commercial payer market dominance), achieve accreditation, then begin ACHC preparation with the documentation infrastructure already in place from the URAC engagement. Policy frameworks developed for URAC often require adaptation rather than complete redevelopment for ACHC — reducing the marginal cost of the second accreditation.
IHS coordinates dual-accreditation strategies and can structure the engagement to maximize documentation overlap between URAC and ACHC requirements.
When to Pursue Only One Program
Single-accreditation is appropriate when your market access goals are clearly served by one program. If your organization serves exclusively commercial managed care clients and has no government program exposure, URAC alone may provide all the market access you need. If your organization serves exclusively Medicare/Medicaid populations and disease-state designations are strategically important, ACHC alone may be sufficient. Review your specific payer mix and contract requirements before committing to dual accreditation resources.
IHS Perspective: How to Choose
IHS consults on both URAC and ACHC pharmacy accreditation programs. Our recommendation framework starts with three questions:
- What do your current and target payer contracts require? Review the accreditation requirements in your existing contracts and in the RFPs of the contracts you are actively pursuing. This is the most reliable indicator of which credential will deliver the most immediate market access value.
- Do you have or seek Medicare/Medicaid pharmacy business? If yes, ACHC's deeming authority has direct regulatory value. If no, this differentiator is less relevant to your decision.
- Does your specialty pharmacy compete on disease-state expertise? If you are positioning as an oncology, HIV, or rare disease specialist, ACHC's disease-state designations provide market differentiation that URAC does not offer.
In most cases, the answer for commercial pharmacy organizations is URAC first, ACHC second if dual accreditation resources are available. For government-program-focused organizations or disease-state specialists, ACHC may be the primary credential with URAC as the secondary.
Thomas G. Goddard, JD, PhD — former Chief Operating Officer and General Counsel of URAC — provides this assessment based on direct institutional knowledge of how URAC standards are developed and applied, combined with IHS's experience across both accreditation bodies.
Schedule a Free Discovery Session
Talk directly with Thomas G. Goddard, JD, PhD — former Chief Operating Officer and General Counsel of URAC — about which pharmacy accreditation program fits your organization's market access goals, payer mix, and operational baseline.